Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIRX |
---|---|---|
09:32 ET | 2276 | 0.9 |
09:36 ET | 6939 | 0.8864 |
09:38 ET | 3510 | 0.88 |
09:50 ET | 112 | 0.9762 |
09:52 ET | 2067 | 0.9899 |
09:54 ET | 2450 | 0.9 |
09:56 ET | 100 | 0.889999 |
09:57 ET | 300 | 0.89 |
10:03 ET | 4983 | 0.86 |
10:12 ET | 283 | 0.8698 |
10:15 ET | 100 | 0.8511 |
10:17 ET | 1410 | 0.869849 |
10:24 ET | 100 | 0.88 |
10:26 ET | 491 | 0.87 |
10:33 ET | 500 | 0.8887 |
10:35 ET | 277 | 0.851001 |
10:37 ET | 14967 | 0.8887 |
10:48 ET | 350 | 0.8984 |
10:51 ET | 700 | 0.9 |
11:02 ET | 100 | 0.9162 |
11:06 ET | 4984 | 0.99 |
11:11 ET | 2447 | 0.98 |
11:15 ET | 104 | 0.9 |
11:49 ET | 100 | 0.97 |
11:54 ET | 100 | 0.97 |
11:58 ET | 675 | 0.9034 |
12:02 ET | 450 | 0.900101 |
12:12 ET | 100 | 0.94 |
12:21 ET | 100 | 0.93 |
12:39 ET | 100 | 0.915 |
12:45 ET | 100 | 0.92737 |
12:48 ET | 1700 | 0.91 |
12:50 ET | 1000 | 0.9003 |
12:56 ET | 100 | 0.9002 |
12:57 ET | 800 | 0.9 |
01:10 ET | 100 | 0.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Viracta Therapeutics Inc | 36.8M | -0.7x | --- |
Brainstorm Cell Therapeutics Inc | 37.0M | -1.2x | --- |
ProMIS Neurosciences Inc | 35.3M | -1.6x | --- |
Eledon Pharmaceuticals Inc | 39.0M | -1.1x | --- |
NRX Pharmaceuticals Inc | 40.0M | -1.0x | --- |
QSAM Biosciences Inc | 32.9M | -4.8x | --- |
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $-1.32 |
Book Value | $0.47 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.